clinical trials

News

Trial finds benefit for GLP-1 agonist in Parkinson’s

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for t

R&D

R&D in 2023 sees focus return to oncology

After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms.

News

Disappointment for BMS as Zeposia fails Crohn’s study

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.

News

Cosmo Feilding Mellen, Beckley Psytech’s chief executive

Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d

Patients

Building the patient experience into observational studies p...

The pharmaceutical industry is facing growing pressure to make drug development more patient-focused.

News

Nanoscope preps filing for retinitis pigmentosa gene therapy

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be u

Trial finds benefit for GLP-1 agonist in Parkinson’s

R&D in 2023 sees focus return to oncology

Disappointment for BMS as Zeposia fails Crohn’s study

Beckley builds case for its psychedelic depression therapy

Building the patient experience into observational studies p...

Nanoscope preps filing for retinitis pigmentosa gene therapy

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks